ArticleCureus2026
Real-World Evaluation of a Trastuzumab Emtansine Biosimilar (Ujvira®) in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antibody-Drug Conjugates: Pharmacotherapeutic Properties and Future Perspectives.Pharmaceutics · 2026Review
- Real-World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer: A Prospective Single-Institution Study From India.International journal of breast cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrastuzumab emtansine (T-DM1) is widely regarded as a standard treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), but its cost puts it beyond the reach of many patients in low- and middle-income countries. Ujvira® (ZRC-3256; Zydus Lifesciences, India), a biosimilar version, could offer a more affordable alternative, although real-world experience with it is still limited.
methodsThis retrospective, single-center study evaluated the efficacy and safety of Ujvira® in patients with HER2-positive MBC treated at a tertiary cancer center in India. All patients had prior trastuzumab exposure and received Ujvira® 3.6 mg/kg intravenously every 21 days until progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS), estimated by the Kaplan-Meier method. Secondary endpoints included objective response rate (ORR), safety (graded per CTCAE v5.0), and exploratory subgroup analyses based on ECOG performance status, hormone receptor expression, comorbidities, and metastatic pattern.
resultsFifty-one patients were included (mean age 58.0 ± 8.4 years; 47 (92.2%) postmenopausal). Median PFS was 6.9 months (95% CI 6.2-9.0) overall, 7.7 months in the second-line setting, and 9.1 months in the third-line setting. The ORR was 35.3%. Treatment was well tolerated; the most common adverse events were thrombocytopenia in 17 patients (33.3%) and anemia in 10 patients (19.6%). Dose reductions occurred in eight patients (15.7%), which did not affect efficacy (PFS 6.8 vs 6.9 months; p = 0.25).
conclusionsIn this real-world Indian cohort, Ujvira® demonstrated efficacy and safety consistent with innovator T-DM1, with preserved outcomes even among heavily pretreated and comorbid patients. These results support Ujvira® as an effective, tolerable, and accessible therapeutic option for HER2-positive MBC in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.